Kathleen N. Moore, MD, discusses the exciting advancements in endometrial cancer treatment, particularly over the past 2 years, as she prepares for the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. She emphasizes the incorporation of immune checkpoint inhibitors with chemotherapy, especially in patients with deficient mismatch repair, and hopes to see improved overall and disease-free survival data.
Dr Moore also expresses interest in emerging treatments, such as antibody-drug conjugates, and how they might interact with immune checkpoint inhibitors in clinical settings. She is optimistic that upcoming studies, especially in the molecular subtypes beyond deficient mismatch repair, will continue to inform better, personalized treatment approaches for patients.
